Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Conference Coverage
Pemigatinib Yields Durable Responses, Prolonged Survival in FGFR2-Altered Cholangiocarcinoma
06/30/2022
Allison Casey
Findings from the phase 2 FIGHT-202 trial reveal pemigatinib demonstrates durable response, prolonged overall survival, and manageable safety in patients with FGFR2-altered advanced of metastatic cholangiocarcinoma.
Findings from the phase 2 FIGHT-202 trial reveal pemigatinib demonstrates durable response, prolonged overall survival, and manageable safety in patients with FGFR2-altered advanced of metastatic cholangiocarcinoma.
Findings from the phase 2...
06/30/2022
Oncology
News
Hepatic Arterial Infusion Pump Floxuridine Chemotherapy vs Resection for Intrahepatic Cholangiocarcinoma
05/19/2022

Amber Denham

Amber Denham
Hepatic arterial infusion pump floxuridine chemotherapy yielded similar OS as resection in patients with multifocal intrahepatic cholangiocarcinoma and may be an effective alternative treatment option, according to a recent study.
Hepatic arterial infusion pump floxuridine chemotherapy yielded similar OS as resection in patients with multifocal intrahepatic cholangiocarcinoma and may be an effective alternative treatment option, according to a recent study.
Hepatic arterial infusion pump...
05/19/2022
Oncology
News
Genomic Profiling Suggests Combined Hepatocellular Cholangiocarcinoma Cases May Be Genomically Subclassified
03/01/2022

John Otrompke

John Otrompke
Study findings suggest that over 70% of combined hepatocellular cholangiocarcinoma cases may be genomically subclassified during treatment into disease which is more similar to hepatocellular carcinoma and cholangiocarcinoma.
Study findings suggest that over 70% of combined hepatocellular cholangiocarcinoma cases may be genomically subclassified during treatment into disease which is more similar to hepatocellular carcinoma and cholangiocarcinoma.
Study findings suggest that over...
03/01/2022
Oncology

Advertisement

News
Association of KRAS Variant Subtypes With Survival, Recurrence in Surgically Treated Intrahepatic Cholangiocarcinoma
02/24/2022

Alexis Hyams

Alexis Hyams
Study findings suggest the presence of G12 KRAS variants are associated with inferior survival and increased risk of recurrence in patients with intrahepatic cholangiocarcinoma.
Study findings suggest the presence of G12 KRAS variants are associated with inferior survival and increased risk of recurrence in patients with intrahepatic cholangiocarcinoma.
Study findings suggest the...
02/24/2022
Oncology
News
Infigratinib Yields PFS, ORR Benefit in Patients With Cholangiocarcinoma and FGFR2 Fusions
07/01/2020
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and...
07/01/2020
Oncology
News
FDA Approves Pemigatinib as First Therapy for Advanced Cholangiocarcinoma
04/20/2020
The FDA has approved pemigatinib for the treatment of adults with certain types of pretreated, advanced cholangiocarcinoma.
The FDA has approved pemigatinib for the treatment of adults with certain types of pretreated, advanced cholangiocarcinoma.
The FDA has approved pemigatinib...
04/20/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use